GSK PLC on Tuesday announced a new positive opinion from the EU’s European Medicine Agency’s Committee for Medicinal Products for Human Use.

The London-based pharmaceutical company said the committee recommended its new single-vial, fully liquid presentation of its invasive meningococcal disease vaccine Menveo.

The recommendation is based on two positive phase 2b trials. GSK expects a final marketing authorisation decision by the European Commission by November.

If approved, it will be available for active immunisation of patients from two years of age upwards, offering healthcare providers an option that does not require reconstitution before use.

Philip Dormitzer, GSK head of Global Vaccines Research & Development said: ‘As a global leader in meningococcal vaccines, we are committed to finding innovative solutions that simplify immunisation against bacterial meningitis, support vaccine uptake and help protect as many people as possible from this devastating disease.

‘We will continue our efforts to help prevent this disease in at-risk populations in the EU.’

GSK shares were 0.1% lower at 1,526.00 pence each on Tuesday morning in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.